SHANGHAI, China, April 17, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that it will host an Analyst & Investor Day on Tuesday, April 30, 2019, beginning at 12:00 p.m. EDT in New York City.
The event will feature a panel of key opinion leaders from China who will discuss the regulatory changes and landscape for innovative oncology therapeutics in China. Senior members of Zai’s management team will provide an overview of the Company’s pipeline and commercial strategy.
Individuals may access a live webcast of the event on the Zai Lab website at www.zailaboratory.com under "Events & Presentations" in the "Investors" section. A replay of the event will be available on its website following the event for 90 days following the live event.
About Zai Lab
Zai Lab (ZLAB) is a China and US-based innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. Zai Lab’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast-growing segments of China's pharmaceutical market and addressing unmet medical needs. Zai Lab's vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partners' and its own products in order to impact human health worldwide.
For more information, please contact:
ZAI LAB CONTACTS:
Billy Cho, CFO
+86 137 6151 2501
Investors: Jill Steier
Burns McClellan, on behalf of Zai Lab
Zai Lab Limited